• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Apollomics Inc.

    5/24/24 5:03:50 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    6-K 1 d717064d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2024

    Commission File Number: 001-41670

     

     

    Apollomics Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Not Applicable

    (Translation of registrant’s name into English)

    989 E. Hillsdale Blvd., Suite 220

    Foster City, California 94404

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form  40-F ☐

     

     

     


    Establishment of “At the Market” Sales Program

    On May 24, 2024, Apollomics Inc., a Cayman Islands exempted company (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (the “Sales Agent”), in connection with the offer and sale from time to time by the Company (the “Offering”) of the Company’s Class A ordinary shares (the “Class A Ordinary Shares”) having an aggregate offering price of up to $19 million, through or to the Sales Agent.

    The issuance and sale, if any, of the Class A Ordinary Shares by the Company under the Sales Agreement will be made pursuant to the Company’s effective registration statement on Form F-3 (Registration Statement No. 333-278430).

    Sales of the Company’s Class A Ordinary Shares, if any, in the Offering may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), from time to time. The Sales Agent will use its commercially reasonable efforts to sell on the Company’s behalf all Class A Ordinary Shares requested to be sold by the Company, consistent with its normal trading and sales practices, on mutually agreed terms. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. Sales may also be conducted, with the Company’s consent, in negotiated transactions.

    The Company will pay the Sales Agent a commission equal to three percent 3.0% of the gross proceeds from sales of any Class A Ordinary Shares sold through the Sales Agent under the Sales Agreement. The Company has agreed to provide indemnification and contribution to the Sales Agent with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.


    The Company is not obligated to make any sales of Class A Ordinary Shares pursuant to the Sales Agreement. This offering of the Company’s Class A Ordinary Shares pursuant to the Sales Agreement will terminate upon the earlier of (1) the sale of $19,000,000 of the Company’s Class A Ordinary Shares or (2) termination of the Sales Agreement as permitted therein. The Company and Sales Agent may each terminate the Sales Agreement at any time upon ten days’ prior notice or by the Sales Agent at any time in certain circumstances, including the occurrence of a material and adverse change in the Company’s business or financial condition that makes it impractical or inadvisable to market the Company’s Class A Ordinary Shares or to enforce contracts for the sale of the Company’s Class A Ordinary Shares.

    The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 and is incorporated herein by reference. A copy of the legal opinion of Conyers Dill & Pearman LLP, the Company’s Cayman counsel, relating to the legality of the issuance of the ordinary shares in the Offering is attached as Exhibit 5.1 hereto.

    This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein.

    The information contained in this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements, including its registration statements on Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549) and registration statement on Form S-8 (File No. 333-272559), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

    EXHIBIT INDEX

     

    Exhibit
    Number

      

    Description of Exhibit

     1.1    Sales Agreement, dated as of May 24, 2024, by and between Apollomics Inc. and Cantor Fitzgerald & Co.
     5.1    Opinion of Conyers Dill & Pearman LLP.
    23.1    Consent of Conyers Dill & Pearman LLP (included in Exhibit 5.1 hereto).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        APOLLOMICS INC.
    Date: May 24, 2024     By:  

    /s/ Guo-Liang Yu

        Name:   Guo-Liang Yu
        Title:   Chief Executive Officer
    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    SEC Filings

    View All

    SEC Form S-8 filed by Apollomics Inc.

    S-8 - Apollomics Inc. (0001944885) (Filer)

    2/2/26 5:30:58 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    12/22/25 4:30:49 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    12/12/25 11:35:36 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apollomics Reports First Half 2025 Financial Results

    FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 2024. Based on current projections, the Company believes its cash position is sufficient to fund planned operations into the third quarter of

    12/22/25 4:05:00 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Announces Settlement of Cayman Litigation

    FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM) announced today entering into a settlement agreement (the "Settlement Agreement" or the "Agreement") with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, "TWVC"), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the "Cayman Litigation"). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company's merger with Maxp

    11/19/25 5:38:35 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Announces Changes to its Board of Directors and Composition of Committees

    FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors ("Board") and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh's resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh's resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a

    11/17/25 11:00:00 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Leadership Updates

    Live Leadership Updates

    View All

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    8/15/24 4:38:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

    SC 13G/A - Apollomics Inc. (0001944885) (Subject)

    5/30/24 4:15:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    5/22/24 7:32:01 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Financials

    Live finance-specific insights

    View All

    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

    Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

    3/28/24 7:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

    FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

    3/26/24 8:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

    Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

    9/28/23 4:17:57 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care